1 of 1
Story summary
- Federal judges heard oral arguments on Louisiana's challenge to the Biden administration's abortion drug policy.
- The 2023 policy removed the FDA’s in-person requirement for mifepristone, which Louisiana says lacks safety data.
- A Fifth Circuit three-judge panel unanimously affirmed Louisiana’s arguments in May and reinstated in-person dispensing.
- The Supreme Court granted the FDA a stay two weeks later, preserving the Biden-era policy.
